title: Primary gastrointestinal lymphoma--disease spectrum and management: a 15-year review from north India.
abstract: OBJECTIVE
  To analyze retrospectively the disease spectrum and outcome of primary gastrointestinal lymphoma (PGIL) in a tertiary referral center in north India.
  
  
  METHODS
  Seventy five patients presenting with PGIL between January 1971 and December 1985 were evaluated.
  
  
  RESULTS
  The 49 males and 26 females were aged 3.5-69 years (mean 34) at presentation. Abdominal pain, weight loss and vomiting were cardinal symptoms at presentation; the stomach was the most common site of involvement. Histologically, a majority of patients were classified as having diffuse poorly-differentiated lymphocytic lymphoma (46.7%) and diffuse histiocytic type (30.7%). Twenty seven (36%) patients had stage I disease, 31 (40%) stage II, 11 (14.7%) stage III, and 6 (8%) stage IV. At laparotomy, primary resection and anastomosis was carried out in 66 patients, while only biopsies were taken in nine. Forty eight patients received adjuvant radiation with or without chemotherapy. The mean follow-up was 3.9 years (range 1-14). The 5-year actuarial survival was 34%, 25% and 16% for stages I, II, and higher-stage disease, respectively. The survival was significantly better (p < 0.01) for gastric location (44%) compared to other sites (24%).
  
  
  CONCLUSIONS
  PGIL was more common in the 3rd and 4th decades of life, with the stomach being the predominant site of involvement. Survival was better among patients with stages I and II disease, and gastric location of lesion.
authors.affiliation: Department of Radiotherapy, Postgraduate Institute of Medical Education and Research, Chandigarh.
authors.forename: D P
authors.initials: DP
authors.lastname: Singh
authors.forename: S C
authors.initials: SC
authors.lastname: Sharma
authors.forename: A P
authors.initials: AP
authors.lastname: Sandhu
authors.forename: M K
authors.initials: MK
authors.lastname: Goenka
authors.forename: R
authors.initials: R
authors.lastname: Kochhar
authors.forename: B
authors.initials: B
authors.lastname: Nagi
authors.forename: R K
authors.initials: RK
authors.lastname: Sur
authors.forename: F D
authors.initials: FD
authors.lastname: Patel
authors.forename: S
authors.initials: S
authors.lastname: Ayyagari
authors.forename: S S
authors.initials: SS
authors.lastname: Bhatia
authors.forename: P
authors.initials: P
authors.lastname: Mukhopadhyay
authors.forename: S
authors.initials: S
authors.lastname: Xavier
authors.forename: D
authors.initials: D
authors.lastname: Bhasin
authors.forename: K
authors.initials: K
authors.lastname: Singh
authors.forename: J D
authors.initials: JD
authors.lastname: Wig
authors.forename: N M
authors.initials: NM
authors.lastname: Gupta
authors.forename: A
authors.initials: A
authors.lastname: Das
authors.forename: B D
authors.initials: BD
authors.lastname: Gupta
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001706:Biopsy; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D005260:Female; D005500:Follow-Up Studies; D005770:Gastrointestinal Neoplasms / Q000453:epidemiology / Q000473:pathology / Q000628:therapy; D006801:Humans; D007194:India / Q000453:epidemiology; D008223:Lymphoma / Q000453:epidemiology / Q000473:pathology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009017:Morbidity; D009367:Neoplasm Staging; D012189:Retrospective Studies; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome